Provided by Tiger Trade Technology Pte. Ltd.

Tempest Therapeutics Inc.

2.36
+0.06002.61%
Volume:11.88K
Turnover:27.24K
Market Cap:11.63M
PE:-0.23
High:2.38
Open:2.30
Low:2.25
Close:2.30
52wk High:12.37
52wk Low:2.17
Shares:4.93M
Float Shares:4.65M
Volume Ratio:0.25
T/O Rate:0.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-10.1030
EPS(LYR):-19.4955
ROE:-405.03%
ROA:-89.32%
PB:1.83
PE(LYR):-0.12

Loading ...

Company Profile

Company Name:
Tempest Therapeutics Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
24
Office Location:
2000 Sierra Point Parkway,Suite 400,Brisbane,California,United States
Zip Code:
94005
Fax:
- -
Introduction:
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.

Directors

Name
Position
Matt Angel
Chief Executive Officer and Director and President
Michael Raab
Chairman of the Board and Director
Christine Pellizzari
Director
Ronit Simantov
Director
Stephen Brady
Director

Shareholders

Name
Position
Matt Angel
Chief Executive Officer and Director and President
Nicholas Maestas
Chief Financial Officer and Corporate Secretary and Head of Corporate Strategy
Samuel Whiting
Chief Medical Officer and Executive Vice President